Zydus receives approval from Health Canada for Mesalamine suppositories

Zydus receives approval from Health Canada for Mesalamine suppositories

By: IPP Bureau

Last updated : October 27, 2025 10:08 am



Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis


Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for generic Mesalamine suppositories 1000 mg.

Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis.

ZDS - Mesalamine suppositories will be manufactured at Zydus Lifesciences Ltd. Changodar, Ahmedabad in Gujarat, India. Mesalamine suppositories had annual sales of 4.86 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).

Zydus Lifesciences Limited Health Canada

First Published : October 27, 2025 12:00 am